13/03/2019 11:05:00

Assembly Biosciences to Participate in the Jefferies 2019 HBV Summit

SAN FRANCISCO, March 13, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Derek Small, Assembly’s President and Chief Executive Officer will participate in the Jefferies 2019 HBV Summit on Monday, March 18, 2019 in New York.

A webcast of the HBV Summit will be available in the Events and Presentations section of the Company’s website at www.assemblybio.com.

           

About Assembly Biosciences

Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live synthetic biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit assemblybio.com.

Contacts

Assembly Biosciences, Inc.

Investors:

Lauren Glaser

(415) 521-3828

lglaser@assemblybio.com 

ASMBlogo.jpg

Related content
27 Jun - 
Assembly Biosciences Announces First Patient Dosed with..
25 Jun - 
Assembly Biosciences Announces Participation in the Mic..
21 Jun - 
Assembly Biosciences Announces Presentation at Internat..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
NSR: Satellite Manufacturing & Launch Services Market to Generate $225 Billion in Next Decade
2
Audited Annual Results year ended 31 January 2019
3
UTStarcom Introduces New SyncRing Products at Softbank World 2019
4
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Teladoc Health (NYSE: TDOC) and Encourages Teladoc Group Investors to Contact the Firm
5
Lifting of suspension of trading

Related stock quotes

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 July 2019 06:23:35
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190703.1 - EUROWEB7 - 2019-07-18 07:23:35 - 2019-07-18 06:23:35 - 1000 - Website: OKAY